metaPreg - Acetaminophen (Neuro-developmental outcomes) during pregnancy

Acetaminophen (Neuro-developmental outcomes) updated on 07-16-2024

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	1.17 [1.08, 1.27]	67%	6 studies	149,447	280,000	serious	ROB	1.61 [1.36; .]
ADHD (Attention deficit hyperactivity disorder): Diagnosis	1.16 [1.05, 1.29]	77%	4 studies	148,170	278,039	not evaluable	ROB	1.60 [1.28; .]
Language disorders/delay	1.00 [0.99, 1.01]	0%	5 studies	1,886	11,739	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Risk	1.15 [1.06, 1.24]	0%	3 studies	3,069	23,631	not evaluable	ROB	1.56 [1.31; .]
ASD (Autism spectrum disorder): Diagnosis	1.10 [0.98, 1.24]	70%	2 studies	69,611	222,096	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis/Risk	1.10 [0.98, 1.24]	70%	2 studies	69,611	222,096	not evaluable	ROB	-
Psychomotor developmental disorders/delay	0.99 [0.89, 1.10]	47%	3 studies	2,586	15,973	not evaluable	ROB	-
Cognitive developmental disorders/delay (< 3 years old)	0.93 [0.83, 1.03]	0%	2 studies		2,470	not evaluable	ROB	-
Cognitive developmental disorders/delay (> 6 years old)	1.05 [1.00, 1.10]	-	1 study	24,554	185,909	not evaluable	ROB	1.28 [1.03; .]
Severe cognitive developmental delay (Mental retardation) (> 6 years old)	1.05 [1.00, 1.10]	-	1 study	24,554	185,909	not evaluable	ROB	1.28 [1.03; .]
ASD (Autism spectrum disorder): Risk	1.28 [1.10, 1.49]	-	1 study	729	34,584	not evaluable	ROB	1.88 [1.43; .]
2 non statistically significant endpoints reported in only one study